בסרמי 500 מקג 0.5 מל
aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b
פרילידן
halperin n.h. medic ltd, israel - lidocaine; prilocaine - קרם - prilocaine 25 mg / 1 g; lidocaine 25 mg / 1 g - prilocaine
מיקוסטר % 8 לק לציפורניים
perrigo israel agencies ltd - ciclopirox - לק - ciclopirox 8 %w/w - ciclopirox
מיקוסטר % 8 לק לציפורניים
perrigo israel agencies ltd - ciclopirox - לק - ciclopirox 8 %w/w - ciclopirox
רפמיון תמיסה
pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.
רילרט 20 מג
pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - טבליות מצופות פילם - eletriptan hydrobromide 24.242 mg - eletriptan
רילרט 40 מג
pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - טבליות מצופות פילם - eletriptan hydrobromide 48.485 mg - eletriptan
רילרט 80 מג
pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - טבליות מצופות פילם - eletriptan hydrobromide 96.97 mg - eletriptan
אינג'י 10 מ"ג/10 מ"ג טבליות
merck sharp & dohme israel ltd - ezetimibe 10 mg; simvastatin 10 mg - tablets - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh.patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).
אינג'י 10 מג20 מג טבליות
merck sharp & dohme israel ltd - ezetimibe; simvastatin - טבליה - simvastatin 20 mg; ezetimibe 10 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh.patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).